Jubilant Pharmova Limited
NSE: JUBLPHARMA BSE: JUBLPHARMA
NSE
1,236.30
83.40 (7.23%)
Prev Close
1152.9
Open Price
1162.6
Volume
1,978,762
Today Low / High
1152.7 / 1248
52 WK Low / High
735.7 / 1309.9
Range
1,174 - 1,298
BSE
1,236.55
82.05 (7.11%)
Prev Close
1154.5
Open Price
1150.05
Volume
81,318
Today Low / High
1150.05 / 1250
52 WK Low / High
734.5 / 1309
Range
1,175 - 1,298
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 1236.3 (target range: 1,174 - 1,298), reflecting a change of 83.4 (7.23393%). On the BSE, it is listed at 1236.55 (target range: 1,175 - 1,298), showing a change of 82.05 (7.10697%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
30 Jul
1,162.60
6.34%
29 Jul
1,176.00
-1.96%
28 Jul
1,178.70
-0.38%
25 Jul
1,171.00
0.65%
24 Jul
1,197.00
-1.84%
23 Jul
1,213.00
-1.36%
22 Jul
1,228.50
-1.48%
21 Jul
1,240.00
-1.42%
18 Jul
1,205.00
2.24%
17 Jul
1,204.40
-0.30%
16 Jul
1,202.60
-0.67%
15 Jul
1,205.80
-0.27%
14 Jul
1,165.70
2.43%
11 Jul
1,173.30
-0.65%
10 Jul
1,150.90
1.82%
09 Jul
1,163.70
-1.27%
08 Jul
1,206.30
-3.39%
07 Jul
1,199.00
0.11%
04 Jul
1,205.00
-0.91%
03 Jul
1,206.00
-0.37%
02 Jul
1,199.40
-0.13%
Jubilant Pharmova Limited Graph
Jubilant Pharmova Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Jubilant Pharmova Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 1,236.30, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 1,236.55 | 1,248.92 | 1,124.02 - 1,373.81 |
| 1,261.28 | 1,009.02 - 1,513.54 | ||
| 1,273.65 | 891.55 - 1,655.74 | ||
| Bearish Scenario | 1,236.55 | 1,224.18 | 1,101.77 - 1,346.60 |
| 1,211.82 | 969.46 - 1,454.18 | ||
| 1,199.45 | 839.62 - 1,559.29 |
Overview of Jubilant Pharmova Limited
ISIN
INE700A01033
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
490,167
Market Cap
196,919,100,300
Last Dividend
10
Official Website
IPO Date
2002-07-01
DCF Diff
655.53
DCF
581
Financial Ratios Every Investor Needs
Stock Dividend of JUBLPHARMA
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-07-25 | July 25, 25 | 5 | 5 | 2025-07-25 | 2025-09-01 | |
| 2024-08-02 | August 02, 24 | 5 | 5 | 2024-08-02 | 2024-09-29 | |
| 2023-08-10 | August 10, 23 | 5 | 5 | 2023-08-10 | 2023-09-30 | |
| 2022-08-11 | August 11, 22 | 5 | 5 | 2022-08-12 | 2022-10-25 | |
| 2021-08-05 | August 05, 21 | 5 | 5 | 2021-08-06 | 2021-10-20 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 7,234.50 Cr | 2,317.00 Cr | 4,917.50 Cr | 0.6797 | 0.00 Cr | 0.00 Cr | 2,649.60 Cr | 839.40 Cr | 52.99 | 1,173.70 Cr | 0.1160 |
| 2024-03-31 | 6,644.80 Cr | 4,738.60 Cr | 1,906.20 Cr | 0.2869 | 0.00 Cr | 226.30 Cr | 523.10 Cr | 77.10 Cr | 4.86 | 808.80 Cr | 0.0116 |
| 2023-03-31 | 6,219.30 Cr | 1,877.93 Cr | 4,341.37 Cr | 0.6980 | 0.00 Cr | 223.08 Cr | 374.88 Cr | -60.98 Cr | -3.83 | 757.75 Cr | -0.0098 |
| 2022-03-31 | 6,059.17 Cr | 1,786.99 Cr | 4,272.18 Cr | 0.7051 | 0.00 Cr | 245.80 Cr | 839.83 Cr | 413.94 Cr | 26.01 | 1,167.62 Cr | 0.0683 |
| 2021-03-31 | 5,963.88 Cr | 1,753.45 Cr | 4,210.42 Cr | 0.7060 | 0.00 Cr | 232.26 Cr | 1,144.25 Cr | 835.87 Cr | 52.48 | 1,392.87 Cr | 0.1402 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 1,088.80 Cr | 12,756.40 Cr | 6,517.80 Cr | 6,254.9000 Cr | 2,731.00 Cr | 1,642.20 Cr | 1,129.20 Cr | 5,168.20 Cr | 0.00 Cr | 0.00 Cr | 43.50 Cr | 2,164.6000 Cr |
| 2024-03-31 | 953.90 Cr | 11,548.50 Cr | 6,127.40 Cr | 5,433.9000 Cr | 3,664.00 Cr | 2,710.10 Cr | 1,303.80 Cr | 3,687.10 Cr | 86.50 Cr | 543.80 Cr | 42.20 Cr | 1,889.0000 Cr |
| 2023-03-31 | 1,013.92 Cr | 11,156.65 Cr | 5,764.86 Cr | 5,399.2800 Cr | 3,676.76 Cr | 2,662.84 Cr | 1,380.53 Cr | 3,365.12 Cr | 476.18 Cr | 268.51 Cr | 256.42 Cr | 1,772.4000 Cr |
| 2022-03-31 | 980.26 Cr | 9,990.87 Cr | 4,674.47 Cr | 5,318.5630 Cr | 3,192.00 Cr | 2,211.74 Cr | 1,254.87 Cr | 2,791.10 Cr | 356.43 Cr | 7.30 Cr | 238.60 Cr | 1,591.6010 Cr |
| 2021-03-31 | 497.94 Cr | 8,918.11 Cr | 4,176.59 Cr | 4,741.4860 Cr | 2,829.56 Cr | 2,331.63 Cr | 1,129.38 Cr | 2,575.19 Cr | 357.26 Cr | 7.57 Cr | 254.09 Cr | 1,048.8330 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 1,072.1000 Cr | 487.7000 Cr | -1,452.7000 Cr | -43.5000 Cr | 131.9000 Cr | 1,088.3000 Cr | -1,115.6000 Cr | 839.4000 Cr | -1,155.3000 Cr | -79.6000 Cr | 78.5000 Cr |
| 2024-03-31 | 971.3000 Cr | -607.9000 Cr | -432.5000 Cr | 73.6000 Cr | -57.5000 Cr | 956.4000 Cr | -897.7000 Cr | 77.1000 Cr | -20.4000 Cr | -79.8000 Cr | 90.8000 Cr |
| 2023-03-31 | 660.6700 Cr | -544.4100 Cr | -156.6900 Cr | -153.7800 Cr | 30.1000 Cr | 1,013.9200 Cr | -814.4500 Cr | 27.7800 Cr | 231.7000 Cr | -80.0610 Cr | -64.6800 Cr |
| 2022-03-31 | 837.5430 Cr | -380.3700 Cr | -32.5990 Cr | 237.5520 Cr | 481.8620 Cr | 983.8190 Cr | -599.9910 Cr | 630.4470 Cr | 138.3920 Cr | -80.0530 Cr | -95.6470 Cr |
| 2021-03-31 | 1,784.2650 Cr | -739.0140 Cr | -1,709.3860 Cr | 1,256.7710 Cr | -728.8570 Cr | 501.9570 Cr | -527.4940 Cr | 1,212.0100 Cr | -1,349.7390 Cr | -1.4750 Cr | 134.3210 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 1,928.80 Cr | 626.10 Cr | 1,302.70 Cr | 0.6754 | 250.20 Cr | 153.60 Cr | 9.71 | 342.35 Cr | 0.0796 |
| 2024-12-31 | 1,813.70 Cr | 574.40 Cr | 1,239.30 Cr | 0.6833 | 196.10 Cr | 100.90 Cr | 6.37 | 277.40 Cr | 0.0556 |
| 2024-09-30 | 1,752.30 Cr | 1,210.50 Cr | 541.80 Cr | 0.3092 | 198.00 Cr | 102.80 Cr | 6.47 | 296.80 Cr | 0.0587 |
| 2024-06-30 | 1,731.70 Cr | 1,205.30 Cr | 526.40 Cr | 0.3040 | 65.50 Cr | 482.10 Cr | 30.51 | 661.40 Cr | 0.2784 |
| 2024-03-31 | 1,758.60 Cr | 1,183.40 Cr | 575.20 Cr | 0.3271 | 170.40 Cr | -58.60 Cr | -3.68 | 116.90 Cr | -0.0333 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 1,088.80 Cr | 0.00 Cr | 1,088.80 Cr | 891.50 Cr | 1,129.20 Cr | 3,577.20 Cr | 5,168.20 Cr | 12,756.40 Cr | 6,517.80 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 1,077.40 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -5,927.00 Cr |
| 2024-09-30 | 1,076.90 Cr | 0.50 Cr | 1,288.50 Cr | 796.20 Cr | 1,161.50 Cr | 3,501.80 Cr | 4,265.90 Cr | 11,924.40 Cr | 5,997.40 Cr |
| 2024-06-30 | -956.80 Cr | 1,913.60 Cr | 956.80 Cr | 0.00 Cr | 0.00 Cr | 956.80 Cr | 0.00 Cr | 0.00 Cr | -5,421.10 Cr |
| 2024-03-31 | 956.80 Cr | 247.80 Cr | 956.80 Cr | 1,013.40 Cr | 1,289.60 Cr | 3,876.10 Cr | 3,687.10 Cr | 11,548.50 Cr | 6,127.40 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 153.60 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 100.90 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 102.80 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 482.10 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | -58.60 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2010-11-25 | November 25, 10 | 21:20 |
| 2006-03-17 | March 17, 06 | 5:1 |
| 2004-03-12 | March 12, 04 | 8:5 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,733.80 | ₹4,159,871,664,000.00 | ₹2,318,664.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,650.00 | ₹1,765,368,850,000.00 | ₹226,973.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,730.60 | ₹1,262,602,917,000.00 | ₹439,520.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,292.10 | ₹1,075,456,274,108.00 | ₹1,386,961.00 |
| Mankind Pharma Limited | MANKIND | ₹2,575.50 | ₹1,062,982,921,380.00 | ₹763,328.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹995.15 | ₹1,001,349,784,500.00 | ₹775,382.00 |
| Lupin Limited | LUPIN | ₹1,984.60 | ₹906,460,096,200.00 | ₹754,124.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,158.00 | ₹672,568,716,000.00 | ₹672,249.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,099.60 | ₹609,733,674,000.00 | ₹69,765.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹2,153.60 | ₹607,748,073,600.00 | ₹786,090.00 |
| Laurus Labs Limited | LAURUSLABS | ₹881.45 | ₹475,603,095,050.00 | ₹5,551,173.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,529.50 | ₹388,040,268,000.00 | ₹501,348.00 |
| Cohance Lifesciences Limited | COHANCE | ₹997.40 | ₹381,572,333,779.00 | ₹30,739.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,800.50 | ₹349,816,056,000.00 | ₹68,739.00 |
| Piramal Enterprises Limited | PEL | ₹1,287.60 | ₹291,870,592,800.00 | ₹4,377,271.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,782.60 | ₹278,652,466,800.00 | ₹198,162.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,684.80 | ₹273,744,619,200.00 | ₹253,355.00 |
| Eris Lifesciences Limited | ERIS | ₹1,816.60 | ₹247,415,470,200.00 | ₹258,998.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹9,340.00 | ₹233,500,000,000.00 | ₹39,783.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹1,007.60 | ₹198,056,878,800.00 | ₹43,245.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,236.30 | ₹196,919,100,300.00 | ₹1,978,762.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,910.00 | ₹178,463,909,000.00 | ₹72,265.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹973.15 | ₹174,300,896,500.00 | ₹709,365.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹2,145.80 | ₹163,105,905,860.00 | ₹121,630.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹492.15 | ₹119,417,244,600.00 | ₹954,418.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,947.00 | ₹98,716,631,800.00 | ₹41,877.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹919.15 | ₹89,884,505,735.00 | ₹41,687.00 |
| Strides Pharma Science Limited | STAR | ₹945.35 | ₹87,126,008,445.00 | ₹401,712.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹946.50 | ₹85,785,667,830.00 | ₹174,284.00 |
| FDC Limited | FDC | ₹484.45 | ₹78,873,304,500.00 | ₹30,593.00 |
| Suven Life Sciences Limited | SUVEN | ₹269.30 | ₹58,727,328,200.00 | ₹85,394.00 |
| Innova Captab Limited | INNOVACAP | ₹917.50 | ₹52,503,873,275.00 | ₹36,415.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹151.93 | ₹49,304,627,460.00 | ₹195,988.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹522.25 | ₹47,665,757,500.00 | ₹446,949.00 |
| Sequent Scientific Limited | SEQUENT | ₹175.86 | ₹44,023,913,100.00 | ₹235,318.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹619.85 | ₹43,641,035,130.00 | ₹39,695.00 |
| Hikal Limited | HIKAL | ₹329.80 | ₹40,664,669,800.00 | ₹316,649.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹404.55 | ₹40,567,464,900.00 | ₹352,761.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,405.80 | ₹39,789,526,200.00 | ₹52,499.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹705.15 | ₹35,764,573,365.00 | ₹37,012.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹59.69 | ₹32,707,374,260.00 | ₹1,444,289.00 |
| Solara Active Pharma Sciences Limited | SOLARA | ₹651.90 | ₹31,390,940,700.00 | ₹124,331.00 |
| Indoco Remedies Limited | INDOCO | ₹324.50 | ₹29,934,443,550.00 | ₹64,322.00 |
| IOL Chemicals and Pharmaceuticals Limited | IOLCP | ₹100.29 | ₹29,437,822,830.00 | ₹15,953,556.00 |
| Alembic Limited | ALEMBICLTD | ₹114.24 | ₹29,334,775,566.00 | ₹212,418.00 |
Key Executives
Company Secretary & Compliance Officer
Mr. Naresh Kapoor
Gender: male
Year Born: 1974
MD & Director
Mr. Priyavrat Bhartia MBA
Gender: male
Year Born: 1976
Executive Vice President of Group Accounts
Mr. Prakash Chandra Bisht B.Com., CA
Gender: male
Year Born: 1965
Executive Vice President & Head of Legal
Mr. Sanjay Gupta A.C.M.A., B.Com., L.L.B.
Gender: male
Year Born: 1966
Group Chief Human Resources Officer
Shantanu Jha
Gender: Not Specified
Year Born:
Advisor
Mr. Rajagopal Sankaraiah B.Sc., CA, F.C.A.
Gender: male
Year Born: 1959
Joint MD & Director
Mr. Arjun Shanker Bhartia
Gender: male
Year Born: 1987
Group Chief Financial Officer & Whole-Time Director
Mr. Arvind Chokhany
Gender: male
Year Born: 1972
Senior Vice President of Corporate Affairs
Mr. A. P. Srivastava B.A., BA
Gender: male
Year Born: 1946
Head of Investor Relations
Surajit Pal
Gender: Not Specified
Year Born:
FAQs about Jubilant Pharmova Limited
Who is the CEO of the company?
The CEO is Priyavrat Bhartia MBA.
What is the current market price of the stock?
The current price is ₹1,236.30.
What is the 52-week price range?
The range is ₹735.7-1309.9.
What is the market capitalization of the company?
The market capitalization is ₹19,691.91 crores.
What is the dividend yield?
The dividend yield is 0.81%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 23.37.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Jubilant Pharmova Limited (ISIN: INE700A01033) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹19,691.91 crores and an average daily volume of 490,167 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹10.